Singapore, July 16 -- The Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately JPY 2.86 billion ($18 million) in six R&D projects for the development of drugs for malaria, tuberculosis (TB) and neglected tropical diseases (NTDs).

The GHIT Fund has decided to invest approximately JPY 910 million ($5.7 million) in a global partnership for preclinical studies of a long-acting injectable (LAI) for malaria prevention. This project is being led by Shionogi, Nagasaki University and Medicines for Malaria Venture (MMV).

This project aims to conduct Chemistry, Manufacturing, and Controls (CMC) research and development, manufacture the active pharmaceutical ingredient (API) and investigational drug prod...